ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.5511G>T (p.Trp1837Cys) (rs80356914)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000049030 SCV000077043 pathogenic Hereditary breast and ovarian cancer syndrome 2020-10-18 criteria provided, single submitter clinical testing This sequence change replaces tryptophan with cysteine at codon 1837 of the BRCA1 protein (p.Trp1837Cys). The tryptophan residue is highly conserved and there is a large physicochemical difference between tryptophan and cysteine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in individuals in the Breast Cancer Information Core database (PMID: 10923033). ClinVar contains an entry for this variant (Variation ID: 37680). This variant has been reported to affect BRCA1 protein function (PMID:20516115, 27802165, 30209399). This variant disrupts the p.Trp1837 amino acid residue in BRCA1. Other variant(s) that disrupt this residue have been observed in individuals with BRCA1-related conditions (PMID: 28324225, 11802209, 27741520, 8968102, 15689452), suggesting that it is a clinically significant residue. As a result, variants that disrupt this residue are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic.
Color Health, Inc RCV000774925 SCV000908977 likely pathogenic Hereditary cancer-predisposing syndrome 2019-10-30 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000049030 SCV000916815 likely pathogenic Hereditary breast and ovarian cancer syndrome 2018-10-23 criteria provided, single submitter clinical testing Variant summary: BRCA1 c.5511G>T (p.Trp1837Cys) results in a non-conservative amino acid change located in the C-terminal BRCT domain (Ghani-Kakhki_2012) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 246126 control chromosomes (gnomAD). c.5511G>T has not been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer. Although, the variant, c.5511G>C, that causes the same missense change has been reported in a BrC patient as a somatic occurrence (Li_2016). Multiple functional studies have been performed on this variant and found it to significantly impact transcriptional activity, binding ability and protein folding (Carvalho_2014, Lee_2010, Thouvenot_2016). In addition, other missense changes affecting this codon, Trp1837Arg and Trp1837Gly, have been reported in affected individuals suggesting a mutational hotspot. A ClinVar submission from a clinical diagnostic laboratory (evaluation after 2014) cites the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Ambry Genetics RCV000774925 SCV001186187 likely pathogenic Hereditary cancer-predisposing syndrome 2018-10-17 criteria provided, single submitter clinical testing The p.W1837C variant (also known as c.5511G>T), located in coding exon 22 of the BRCA1 gene, results from a G to T substitution at nucleotide position 5511. The tryptophan at codon 1837 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration is located in the BRCT domain and has been found to impair nuclear localization, transcriptional activation, and in vivo protein folding (Lee MS et al. Cancer Res. 2010 Jun; 70(12):4880-90; Thouvenot P et al. J. Cell. Sci., 2016 12;129:4366-4378). Several other missense alterations, including p.W1837R and p.W1837G, have also been shown to be structurally and functionally deficient. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Sharing Clinical Reports Project (SCRP) RCV000031261 SCV000053865 uncertain significance Breast-ovarian cancer, familial 1 2010-09-10 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000031261 SCV000145562 uncertain significance Breast-ovarian cancer, familial 1 2004-11-25 no assertion criteria provided clinical testing
Brotman Baty Institute,University of Washington RCV000031261 SCV001244042 not provided Breast-ovarian cancer, familial 1 no assertion provided in vitro

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.